Give yourself an answer at 7 weeks of your pregnancy.
Give yourself an answer at 7 weeks of your pregnancy.
Vangenes group has completed more than 50,000 Non-invasive Prenatal Paternity Test (NIPPT) cases globally in the past six years. We are trusted by customers from countries.
To make technology better serve people, we keep applying higher standards and better solutions to our products. Vangenes Group holds patents for NIPPT and developed high-sensitive multi-cancer early screening technology.
Vangenes Group was founded in China in 2013. We develop and commercialize diagnostic tests for reproductive health and cancer early screening. Utilizing the advanced well-known platform of Next Generation Sequencing, our team has developed a high standard of lab processes from sampling, sequencing to data analysis on non-invasive prenatal DNA tests (Related Research Publications by Vangenes ). Vangenes HK is our subsidary in Hong Kong.
Related Articles
An adaptive detection method for fetal chromosomal aneuploidy using cell-free DNA from 447 Korean women
Comparison of two high-throughput semiconductor chip sequencing platforms in noninvasive prenatal testing for Down syndrome in early pregnancy
The Feasibility Study of Non-Invasive Fetal Trisomy 18 and 21 Detection with Semiconductor Sequencing Platform
Related Patents
"Method for Judging Antenatal Parental Right Relation with SNP" (patent number ZL201510390373.9)
“Quantitative method for free fetal DNA (deoxyribonucleic acid) proportion in maternal peripheral blood” (patent number ZL201510225771.5)
The technique is just the method of how we serve our customers. We care about our customers' feelings when they are having our service. Our professionals will satisfy most of our customer's needs as much as we can. We provide home collection service, privacy protection, and so on. We want every customer to have an experience that is enjoyable, efficient, and convenient during our tests or service.